对比HER-2及性激素受体在乳腺癌原发灶及配对复发转移灶之间的表达  

Comparison of HER - 2 and hormone receptor expression in primary breast cancers and paired metastases

作　　者：傅芳萌[1] 王川[1] 康德勇[1] 许国玺[1] 陈勇武[1] 黄建平[1] 

机构地区：[1]福建医科大学附属协和医院,350001

出　　处：《中国医学创新》2010年第7期8-10,共3页Medical Innovation of China

摘　　要：目的研究ER、PR、HER-2受体表达在乳腺癌原发灶和复发转移灶之间是否存在着差异及其相应的临床意义。方法采用免疫组织化学染色方法检测42例复发转移乳腺癌病例中ER、PR、HER-2受体在原发灶及复发转移灶之间的表达差异。结果ER和HER-2受体在原发灶及复发转移灶表达的不一致率分别为28．6％（P〈0．05）和38．1％（0．005〈P〈0．01）．而PR的表达不一致率为33．3％，统计学上无显著性差异；原发灶ER表达缺失及HER-2受体过表达具有良好的预测价值。结论进展期乳腺癌中，原发灶同复发转移灶性激素受体及HER-2受体表达存在显著性差异，在临床实践中应该考虑这些差别。Objective To investgate the discordance of expression of hormone receptors and HER - 2 （ human epidermal growth factor receptor - 2 ） between the primary and metastatic focuses in breast cancer patients and its clinical significance. Methods Forty - two cases with available samples from primary and metaststic tumors were enrolled. HR and HER - 2 status were assessed by IHC. Results The discordance rate for ER and HER - 2 status was 28.6% （ P 〈 0. 05 ） and 38. 1% （0. 005 〈 P 〈 0. 01 ） respectively. No significant discordance for PR status （33.3%）was found. Defiencent expression of ER and overexpressiou of HER - 2 well predicted the immanostaining results of metastasis. Conclusion The changes of HR and HER - 2 expression status between primay and metastatic sites in advanced breast cancer patients were significant. Therefore we should take the expression differences of HR and HER -2 into consideration in our clinical pratices.

关 键 词：乳腺癌 性激素受体 HER-2受体 免疫组织化学 

分 类 号：R394.4[医药卫生—医学遗传学]